Department of Nano-Therapeutics, Institute of Nano Science and Technology, Habitat Centre, Phase 10, Sector 64, Mohali, Punjab 160062, India.
Department of Biology, College of Science and Humanities, Prince Sattam bin Abdulaziz University, PO box 173, Alkharj, 11942, Saudi Arabia.
Int J Biol Macromol. 2021 Apr 1;175:1-18. doi: 10.1016/j.ijbiomac.2021.01.152. Epub 2021 Jan 27.
Administration of nanomaterials based medicinal and drug carrier systems into systemic circulation brings about interaction of blood components e.g. albumin and globulin proteins with these nanosystems. These blood or serum proteins either get loosely attached over these nanocarriers and form soft protein corona or are tightly adsorbed over nanoparticles and hard protein corona formation occurs. Formation of protein corona has significant implications over a wide array of physicochemical and medicinal attributes. Almost all pharmacological, toxicological and carrier characteristics of nanoparticles get prominently touched by the protein corona formation. It is this interaction of nanoparticle protein corona that decides and influences fate of nanomaterials-based systems. In this article, authors reviewed several diverse aspects of protein corona formation and its implications on various possible outcomes in vivo and in vitro. A brief description regarding formation and types of protein corona has been included along with mechanisms and pharmacokinetic, pharmacological behavior and toxicological profiles of nanoparticles has been described. Finally, significance of protein corona in context of its in vivo and in vitro behavior, involvement of biomolecules at nanoparticle plasma interface and other interfaces and effects of protein corona on biocompatibility characteristics have also been touched upon.
将基于纳米材料的药物和药物载体系统施用于体循环会引起血液成分(例如白蛋白和球蛋白蛋白质)与这些纳米系统相互作用。这些血液或血清蛋白质要么松散地附着在这些纳米载体上形成软蛋白冠,要么紧密吸附在纳米颗粒上形成硬蛋白冠。蛋白冠的形成对广泛的物理化学和药物特性有重要影响。几乎所有纳米颗粒的药理学、毒理学和载体特性都受到蛋白冠形成的明显影响。正是这种纳米颗粒蛋白冠的相互作用决定并影响了基于纳米材料的系统的命运。在本文中,作者综述了蛋白冠形成的几个不同方面及其对体内和体外各种可能结果的影响。简要描述了蛋白冠的形成及其类型,以及纳米颗粒的机制和药代动力学、药理学行为和毒理学特征。最后,还探讨了蛋白冠在体内和体外行为、生物分子在纳米颗粒血浆界面和其他界面的参与以及蛋白冠对生物相容性特征的影响的重要性。
Int J Biol Macromol. 2021-4-1
Mol Pharm. 2020-3-2
Acc Chem Res. 2021-1-19
Chem Commun (Camb). 2020-8-7
Adv Exp Med Biol. 2018
Drug Deliv Transl Res. 2020-6
Nanomedicine (Lond). 2017-10-10
J Nanobiotechnology. 2025-2-25
Materials (Basel). 2024-12-30
ACS Nano. 2025-2-4
bioRxiv. 2024-8-26
Wiley Interdiscip Rev Nanomed Nanobiotechnol. 2024